SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 3558742
• 负责人: RICHARD I FISHER
• 金额: $ 22.23万
• 依托单位: LOYOLA UNIVERSITY CHICAGO
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558742
• 关键词: Hodgkin's disease; acute myelogenous leukemia; adenocarcinoma; antineoplastics; bone marrow transplantation; brain neoplasms; breast neoplasms; carmustine; cis platinum compound; clinical trials; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cytosine arabinoside; etoposide; flow cytometry; gastrointestinal neoplasms; glioma; head /neck neoplasm; human subject; human therapy evaluation; hydroxyurea; interferon alpha; interleukin 2; kidney neoplasms; lung neoplasms; lymph node neoplasm; lymphoma; melanoma; mesothelioma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer remission /regression; neoplasm /cancer surgery; nephrectomy; nonHodgkin's lymphoma; ovary neoplasms; pancreas neoplasms; passive immunization; postmenopause; prognosis; renal cell carcinoma; sarcoma; small cell lung cancer; squamous cell carcinoma; stomach neoplasms; tamoxifen; uterus neoplasms

Loyola has made significant scientific contributions to the Southwest Oncology Group during this institution's first grant cycle. Five faculty members have served as Chairs of committees or subcommittees: Dr. Fisher, Chairman, Lymphoma Committee; Dr. Albain, Chairperson, Committee on Women's Health; Dr. Flanigan, Chairman, Renal Subcommittee; Dr. Herman, Chairman, Flow Cytometry Subcommittee; and Dr. Sosman, Vice-Chairman, Melanoma Biology Subcommittee. As such they have been responsible for developing the scientific initiatives of their committees. Twelve Loyola faculty have served as either Principal Coordinator or Co-coordinator for 43 protocols. Eighteen of these protocols were developed based on pilot studies conducted by Loyola investigators, particularly those involving Phase II drug development and the lymphomas. As a result of their scientific contributions, Loyola faculty have been authors on 20 published manuscripts and 17 abstracts. Loyola's increasing administrative and scientific contributions are documented in the "Summary of Contributions" reports issued annually by SWOG: Loyola has moved from an average third quartile ranking in these categories in 1988 to an average first quartile ranking in 1990 and 1991. Loyola also believes that it has made a strong contribution to SWOG scientific activities through its accrual of large number of eligible and evaluable patients to SWOG clinical trials. The number of Loyola registrations has increased significantly in the last two years. Loyola SWOG registrations ranged from 86 to 98 from 1987 to 1989, but rose to 148 in 1990 and 144 in 1991. Between 82 to 87% of these registrations come from the member institution hospitals. Furthermore the current accrual figures do not represent the full accrual potential of the two newest member institution hospitals. MacNeal has accrued patients only in the second half of 1991 and Illinois Masonic accrual will begin in 1992. Finally the quality of data is demonstrated by the fact that throughout this grant cycle the percent of eligible and evaluable patients has ranged from 91 to 100. Support is requested for continued group participation and data management during the next grant cycle.

洛约拉（Loyola）为西南部做出了重大科学贡献 该机构的第一个赠款周期中的肿瘤学小组。 五个教师 成员曾担任委员会或小组委员会主席：费舍尔博士， 淋巴瘤委员会主席； Albain博士，委员会​​主席 妇女健康；肾脏小组委员会主席Flanigan博士；赫尔曼博士， 流式细胞仪小组委员会主席；以及副主席Sosman博士， 黑色素瘤生物学小组委员会。 因此，他们负责 制定委员会的科学计划。 十二个洛约拉 教师曾担任首席协调员或协调员 43个协议。 其中18个协议是根据飞行员开发的 洛约拉研究人员进行的研究，尤其是涉及的研究 II期药物发展和淋巴瘤。 由于他们 科学贡献，洛约拉教师是20 出版的手稿和17个摘要。 洛约拉的增加 行政和科学贡献记录在 Swog每年发布的“捐款摘要”报告：Loyola有 从1988年的这些类别中的平均第三四分位数排名转移 1990年和1991年平均第一个四分位数排名。 认为它为挥杆科学做出了巨大贡献 通过其合格和可评估的大量合格和可评估的活动 患者徘徊临床试验。 Loyola注册的数量 在过去的两年中，有了显着增长。 Loyola Swog注册 从1987年到1989年的86到98不等，但在1990年升至148和144 1991年。这些注册的82％至87％来自会员 机构医院。 此外，当前的应计数字没有 代表两个最新会员机构的全部应计潜力 医院。 麦克尼尔仅在1991年下半年才累积患者 伊利诺伊州共济会应计于1992年开始。最后 数据证明了以下事实：在整个赠款周期中 合格和可评估的患者的百分比为91至100。 请求继续进行小组参与和数据的支持 在下一个赠款周期中的管理。